Markt für gerinnungshemmende Medikamente – Erkenntnisse aus globaler und regionaler Analyse – Prognose bis 2031

  • Report Code : TIPRE00004954
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 154
Buy Now

[Forschungsbericht]Der Markt für Antikoagulanzien-Umkehrmedikamente wird bis 2027 voraussichtlich 2.276,54 Millionen US-Dollar erreichen, gegenüber 922,55 Millionen US-Dollar im Jahr 2019; Es wird geschätzt, dass der Markt von 2020 bis 2027 mit einer jährlichen Wachstumsrate von 12,6 % wachsen wird.



Antikoagulanzien-Umkehrmedikamente sind erforderlich, um die Wirkung der Antikoagulation in bestimmten Situationen wie ungeplanten Operationen, Überdosierung einer Antikoagulanzientherapie und unkontrollierten Eingriffen umzukehren Blutung. Antikoagulationshemmende Medikamente werden bei Erkrankungen wie venöser Thromboembolie, Vorhofflimmern (AF), mechanischem Klappenersatz und anderen Gerinnungsstörungen wie dem Antiphospholipid-Antikörper-Syndrom und Faktor-V-Leiden eingesetzt. Das Wachstum des Marktes für Antikoagulanzien-Umkehrmedikamente wird hauptsächlich auf Faktoren wie die steigende Prävalenz von Vorhofflimmern (AFib) und Schlaganfall zurückgeführt. Allerdings schränken die hohen Kosten für gerinnungshemmende Medikamente das Marktwachstum ein.



Lukrative regionale Märkte für gerinnungshemmende Medikamente



Markteinblicke



Anstieg der Prävalenz von Vorhoferkrankungen Flimmern (AFib)



Orale Antikoagulanzien werden häufig eingesetzt und sind hochwirksam bei der Vorbeugung von Thromboembolien bei AFib-Patienten. Allerdings kann die Verwendung von Antikoagulanzien bei Vorhofflimmern-Patienten zu Blutungen führen; Daher werden gerinnungshemmende Medikamente eingesetzt, um Blutungen zu verhindern.



Nach Angaben der Centers for Disease Control and Prevention (CDC) wurde Vorhofflimmern im Jahr 2018 in den USA auf rund 175.326 Sterbeurkunden erwähnt und war bei etwa 25.845 dieser Todesfälle die Haupttodesursache. Darüber hinaus wird erwartet, dass bis 2030 in den USA 12,1 Millionen Menschen an Vorhofflimmern leiden werden.



Darüber hinaus waren laut der European Society of Cardiology (ESC) im Jahr 2016 7,6 Millionen Menschen über 65 Jahre alt in der EU hatten Vorhofflimmern und es wird erwartet, dass die Zahl bis 2060 um 89 % auf 14,4 Millionen ansteigen wird. Ebenso leiden laut Stroke Association: State of the Nation 2017 mehr als 1 Million Menschen im Vereinigten Königreich an Vorhofflimmern Flimmern.



Daher dürfte eine derart hohe Prävalenz von Vorhofflimmern auf der ganzen Welt das Wachstum des Marktes begünstigen.



Produktbasierte Erkenntnisse



Basierend auf dem Produkt Der Markt für gerinnungshemmende Medikamente ist in Prothrombinkomplexkonzentrate, Vitamin K, Protamin, Tranexamsäure, Idarucizumab und AndeXXa unterteilt. Das Segment der Prothrombinkomplexkonzentrate hielt 2019 den größten Marktanteil; wohingegen das AndeXXa-Segment im Prognosezeitraum voraussichtlich die höchste CAGR auf dem Markt verzeichnen wird. Prothrombinkomplexkonzentrate werden häufig als zuverlässige und schnelle Alternative zu frisch gefrorenem Plasma eingesetzt und kontrollieren übermäßige Blutungen.



Markt für Antikoagulanzien-Umkehrmedikamente nach Produkt – 2019 und 2027



Vertriebskanalbasierte Einblicke



Basierend auf dem Vertriebskanal wird der Markt für Antikoagulanzien-Umkehrmedikamente segmentiert Krankenhausapotheken, Einzelhandelsapotheken und andere. Das Segment der Krankenhausapotheken hielt 2019 den größten Marktanteil und verzeichnete im Prognosezeitraum schätzungsweise die höchste CAGR im Markt.



Strategische Einblicke



Produkteinführungen und -zulassungen sind die von Unternehmen häufig angewandten Strategien zur Erweiterung ihrer globalen Präsenz und ihres Produktportfolios. Zusammenarbeit ist eine der Hauptstrategien der Marktteilnehmer für Antikoagulanzien-Umkehrmedikamente, um den Kundenstamm weltweit zu vergrößern, was ihnen auch ermöglicht, ihren Markennamen weltweit aufrechtzuerhalten.



Markt für Antikoagulanzien-Umkehrmedikamente – nach Produkt




  • Prothrombin-Komplex-Konzentrate

  • Vitamin K

  • Protamin

  • Tranexamsäure

  • Idarucizumab

  • AndeXXa

Markt für Antikoagulanzien-Umkehrmedikamente – nach Vertriebskanal




  • Krankenhausapotheken

  • Einzelhandelsapotheken

  • Andere< /li>

Markt für Antikoagulanzien-Umkehrmedikamente – nach Geografie




  • Nordamerika

    • USA

    • Kanada
    • Mexiko



  • Europa

    • Frankreich

    • Deutschland

    • Italien

    • Großbritannien< /li>
    • Spanien

    • Restliches Europa



  • Asien-Pazifik (APAC)

    • China
    • Indien

    • Südkorea

    • Japan

    • Australien

    • Übriger Asien-Pazifik-Raum



  • Naher Osten und Afrika (MEA)

    • Südafrika

    • Saudi-Arabien

    • VAE

    • Rest von MEA
    • < /ul>
    • Süd- und Mittelamerika

      • Brasilien

      • Argentinien

      • Übriges Süd- und Mittelamerika


    Unternehmensprofile




    • Boehringer Ingelheim International GmbH

    • Pfizer Inc

    • Octapharma AG
    • < li>Amag Pharmaceuticals, Inc
    • Fresenius Kabi AG

    • Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)

    • CSL Limited

    • China Biologic Products, Inc

    • Grifols, SA

    • Shanghai RAAS Blood Products Co., Ltd.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What anticoagulant reversal drugs?

Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned surgery, overdose of anticoagulant therapy, and uncontrolled bleeding. In medical conditions such as venous thromboembolism, atrial fibrillation (AF), mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome, Factor V Leiden, anticoagulant reversal drugs are used.

What are the driving factors for the anticoagulant reversal drugs market across the globe?

The factors that are driving growth of the market are rise in prevalence of atrial fibrillation (AFib) and increase in prevalence of stroke are the major factors driving the market growth. However, high cost of anticoagulant reversal drugs is hindering the market growth.

Who are the major players in the anticoagulant reversal drugs market?

The anticoagulant reversal drugs market majorly consists of the players such as Boehringer Ingelheim International GmbH; Pfizer Inc; Octapharma AG; Amag Pharmaceuticals, Inc; Fresenius Kabi AG; Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals); CSL Limited; China Biologic Products, Inc; Grifols, S.A, and Shanghai RAAS Blood Products Co., Ltd. amongst others.

The List of Companies - Anticoagulant Reversal Drugs Market

  1. Boehringer Ingelheim International GmbH
  2. Pfizer Inc.
  3. Octapharma AG
  4. AMAG PHARMACEUTICALS, INC.
  5. Fresenius Kabi AG
  6. Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
  7. CSL Limited
  8. China Biologic Products, Inc
  9. Grifols, S.A.
  10. Shanghai RAAS Blood Products Co.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports